Olmesartán/Amlodipino/Hidroclorotiazida Aurovitas (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan blocks the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone‑mediated sodium retention. Amlodipine inhibits L‑type calcium channels, causing arterial smooth‑muscle relaxation. Hydrochlorothiazide reduces sodium and water reabsorption in the distal tubule, decreasing plasma volume. Together they produce a complementary reduction in peripheral resistance and intravascular volume.

The prescribed dose is determined by the treating physician based on the individual’s blood‑pressure response, renal function, and any concomitant therapies. The product is supplied in fixed‑strength tablets, and the clinician selects the appropriate strength and dosing frequency for each patient.

The combination is contraindicated in pregnancy because olmesartan and hydrochlorothiazide can cause fetal toxicity, including renal dysfunction and skeletal malformations. Limited data exist for breastfeeding; generally the product is not recommended during lactation unless the benefits outweigh potential risks, and a healthcare professional should evaluate each case.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After submission, the sales team verifies trade or institutional credentials and replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with single‑agent therapy, the fixed‑dose combination offers greater blood‑pressure reduction through three complementary mechanisms, often allowing once‑daily dosing and improving adherence. Relative to other triple combos (e.g., losartan/amlodipine/HCTZ), olmesartan provides a more potent AT1 blockade, while the safety profile remains similar, with comparable risks of electrolyte disturbances and renal effects.

Store the tablets at room temperature, below 25 °C. Keep them in the original blister pack, protect from moisture and direct light, and keep out of reach of children. No refrigeration is required for this oral solid dosage form.

Olmesartan/Amlodipine/Hydrochlorothiazide is taken orally, usually once daily. It may be taken with or without food, but a full glass of water should be used to ensure the tablet is swallowed completely. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include severe hypotension, angioedema, acute renal impairment, significant electrolyte imbalances (especially hyperkalemia or hyponatremia), and hepatic dysfunction. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, marked weakness, or any signs of liver injury.

The combination should be avoided in individuals with known hypersensitivity to any component, severe renal or hepatic impairment, pregnant women, and patients concurrently using contraindicated drugs such as ACE inhibitors, other ARBs, or potassium‑sparing diuretics. Clinicians should also assess suitability in patients with unstable angina or recent myocardial infarction.